Deutsche Bank AG Increases Holdings in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

Deutsche Bank AG grew its stake in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) by 47.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,567,535 shares of the biotechnology company's stock after purchasing an additional 504,336 shares during the period. Deutsche Bank AG owned about 0.98% of Ironwood Pharmaceuticals worth $6,944,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in IRWD. Renaissance Technologies LLC boosted its holdings in Ironwood Pharmaceuticals by 5.5% during the fourth quarter. Renaissance Technologies LLC now owns 9,066,241 shares of the biotechnology company's stock worth $40,163,000 after buying an additional 469,043 shares in the last quarter. Pacer Advisors Inc. raised its position in shares of Ironwood Pharmaceuticals by 4.0% in the fourth quarter. Pacer Advisors Inc. now owns 11,730,771 shares of the biotechnology company's stock worth $51,967,000 after acquiring an additional 450,949 shares during the period. Federated Hermes Inc. purchased a new stake in shares of Ironwood Pharmaceuticals during the 4th quarter worth about $1,641,000. Los Angeles Capital Management LLC grew its position in shares of Ironwood Pharmaceuticals by 2,625.1% during the 4th quarter. Los Angeles Capital Management LLC now owns 331,700 shares of the biotechnology company's stock valued at $1,469,000 after acquiring an additional 319,528 shares during the period. Finally, Walleye Capital LLC increased its stake in shares of Ironwood Pharmaceuticals by 107.0% in the 4th quarter. Walleye Capital LLC now owns 580,097 shares of the biotechnology company's stock valued at $2,570,000 after purchasing an additional 299,798 shares in the last quarter.

Analysts Set New Price Targets

IRWD has been the topic of several research analyst reports. Jefferies Financial Group reissued a "hold" rating and issued a $0.70 price objective (down from $8.00) on shares of Ironwood Pharmaceuticals in a report on Tuesday, April 15th. Leerink Partners cut their price target on shares of Ironwood Pharmaceuticals from $3.00 to $1.00 and set a "market perform" rating for the company in a report on Monday, April 14th. Citizens Jmp downgraded shares of Ironwood Pharmaceuticals from an "outperform" rating to a "market perform" rating in a report on Monday, April 14th. Wells Fargo & Company reissued an "equal weight" rating and set a $1.00 target price (down previously from $7.00) on shares of Ironwood Pharmaceuticals in a research note on Tuesday, April 15th. Finally, StockNews.com upgraded shares of Ironwood Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Thursday, May 8th. Seven research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Hold" and a consensus price target of $4.78.

Ironwood Pharmaceuticals Price Performance

NASDAQ IRWD traded down $0.06 during trading hours on Wednesday, hitting $0.59. 2,197,090 shares of the company's stock traded hands, compared to its average volume of 2,553,854. The company has a market capitalization of $95.31 million, a PE ratio of -19.63 and a beta of 0.37. Ironwood Pharmaceuticals, Inc. has a 52-week low of $0.53 and a 52-week high of $7.11. The firm's 50-day moving average is $1.03 and its 200-day moving average is $2.49.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last issued its earnings results on Wednesday, May 7th. The biotechnology company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.09). Ironwood Pharmaceuticals had a negative return on equity of 0.96% and a negative net margin of 0.65%. The company had revenue of $41.14 million for the quarter, compared to analyst estimates of $67.02 million. Equities research analysts predict that Ironwood Pharmaceuticals, Inc. will post 0.1 earnings per share for the current fiscal year.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.